Privia Health price target raised to $40 from $25 at Piper Sandler

Piper Sandler raised the firm’s price target on Privia Health (PRVA) to $40 from $25 and keeps an Overweight rating on the shares. In the “rough sea” of VBC, the firm believes Privia Health “is a rock.” The company was the first in its Primary Care v2.0 class to appreciate the perverse incentives and unit economic risks of full capitation in MA. Privia preferred shrewd contracts and hand-picked partnerships to unbridled growth, Piper says. Now, on reckoning day for VBC, Privia likely feels no pain, the firm argues.